Inject immediately ... then start Bydureon BCise. Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Do not share pens between patients. History of pancreatitis ...
The European Commission (EC) has approved AstraZeneca’s Bydureon BCise ... better weight loss results and a new injection pen. AstraZeneca announced that the EC green-lighted the new formulation ...
Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback